CBE Pure Solutions

Executive Summary

CBE Pure Solutions is an Australian contract manufacturing organization (CMO) specializing in small-scale sterile fill-finish, aseptic processing, and microbiological testing for clinical-trial materials and commercial therapeutics. Operating from GMP-licensed isolator units and leveraging a rapid sterility microbiology platform, the company provides on-shore manufacturing for biologics, vaccines, and small-molecule drugs across all trial phases. Serving biotech and pharma clients in Australia and the broader Asia-Pacific region, CBE Pure Solutions addresses a critical need for compliant, high-quality manufacturing capacity in the region. The company is positioned to benefit from increasing demand for domestic production of advanced therapies and clinical supplies, supported by government initiatives to strengthen local pharmaceutical manufacturing. As a privately held, revenue-generating CMO with 50–200 employees, it is well-placed to capture growth through capacity expansion and strategic partnerships.

Upcoming Catalysts (preview)

• 2026 Q4Capacity expansion for sterile fill‑finish lines to meet rising clinical‑trial demand75% success
• 2026 Q3Strategic partnership or long‑term contract with a major APAC biotech or pharmaceutical company60% success
• 2026 Q4Regulatory accreditation for new GMP isolator units or rapid sterility testing service expansion80% success